 Alanine
"Alanine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
| Descriptor ID |
D000409
|
| MeSH Number(s) |
D12.125.042
|
| Concept/Terms |
Alanine- Alanine
- Alanine, L-Isomer
- Alanine, L Isomer
- L-Isomer Alanine
- L-Alanine
- L Alanine
|
Below are MeSH descriptors whose meaning is more general than "Alanine".
Below are MeSH descriptors whose meaning is more specific than "Alanine".
This graph shows the total number of publications written about "Alanine" by people in this website by year, and whether "Alanine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 0 | 3 | | 1997 | 0 | 1 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 4 | 4 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 4 | 4 | | 2004 | 1 | 2 | 3 | | 2005 | 0 | 3 | 3 | | 2006 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 2 | 3 | | 2012 | 1 | 1 | 2 | | 2013 | 0 | 3 | 3 | | 2015 | 0 | 1 | 1 | | 2019 | 0 | 2 | 2 | | 2020 | 0 | 7 | 7 | | 2021 | 4 | 8 | 12 | | 2022 | 1 | 1 | 2 | | 2023 | 0 | 3 | 3 | | 2024 | 6 | 2 | 8 | | 2025 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Alanine" by people in Profiles.
-
Mainella VA, Branchford B, Nemkov T, Hosford S, Coyle RP, Johnson B, Choi YJ, Williams M, Zheng JH, Bushman L, Kiser JJ, Anderson PL, Brooks KM. Cellular pharmacology of tenofovir alafenamide and emtricitabine in neutrophils and platelets in people with and without HIV. J Antimicrob Chemother. 2025 May 02; 80(5):1224-1232.
-
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 study. J Int AIDS Soc. 2025 May; 28(5):e26502.
-
Coyle RP, Morrow M, Mann SC, Mainella V, Ellis SL, Schwab S, Coppinger C, Barker N, Ellison L, Zheng JH, Al Zuabi S, Alpert PE, Carnes TC, Buffkin DE, Chai PR, Bushman LR, Kiser JJ, MaWhinney S, Brooks KM, Anderson PL, Castillo-Mancilla JR. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine-Based Antiretroviral Therapy (QUANTI-TAF). Clin Infect Dis. 2024 11 22; 79(5):1233-1241.
-
Brooks KM, Baltrusaitis K, Clarke DF, Nachman S, Jao J, Purswani MU, Agwu A, Beneri C, Deville JG, Powis KM, Stek AM, Eke AC, Shapiro DE, Capparelli E, Greene E, George K, Yin DE, Jean-Philippe P, Chakhtoura N, Bone F, Bacon K, Johnston B, Reding C, Kersey K, Humeniuk R, Best BM, Mirochnick M, Momper JD. Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032. J Infect Dis. 2024 Oct 16; 230(4):878-888.
-
Joseph Davey D, Dadan S, Bheemraj K, Waitt C, Khoo S, Myer L, Wiesner L, Else L, Thompson B, Castel S, Wara N, Anderson PL, Orrell C. Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK study. Antiviral Res. 2024 Nov; 231:106014.
-
Riddler SA, Kelly CW, Hoesley CJ, Ho KS, Piper JM, Edick S, Heard F, Doncel GF, Johnson S, Anderson PL, Brand RM, Kunjara Na Ayudhya RP, Bauermeister JA, Hillier SL, Hendrix CW. A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention. J Infect Dis. 2024 Sep 23; 230(3):696-705.
-
Molina KC, Webb BJ, Kennerley V, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Aggarwal NR, Ginde AA. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5. BMC Infect Dis. 2024 Aug 08; 24(1):802.
-
Kousari AE, Wilson MP, Hawkins KL, Bandali MM, Henao-Mart?nez AF, Gardner EM, Erlandson KM. Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV. HIV Res Clin Pract. 2024 12; 25(1):2339576.
-
Patel N, Morris S, Burke L, Chow K, Pacheco D, Anderson P, Stancyzk F, Blumenthal J. No observed bidirectional effect between tenofovir diphosphate concentrations and gender-affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis. Br J Clin Pharmacol. 2024 Oct; 90(10):2360-2365.
-
Schimmel J, Epperson LC, Aldy K, Wax P, Brent J, Buchanan J, Levine M, Burkhart K. Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry. Drugs. 2024 Feb; 84(2):209-217.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|